Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Diabetes

  Free Subscription


Articles published in Diabetes Obes Metab

Retrieve available abstracts of 258 articles:
HTML format
Text format



Single Articles


    October 2018
  1. AL-QAISSI A, Papageorgiou M, Javed Z, Heise T, et al
    Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus.
    Diabetes Obes Metab. 2018 Oct 12. doi: 10.1111/dom.13555.
    PubMed     Text format     Abstract available


  2. BJORNSTAD P, Singh SK, Snell-Bergeon JK, Lovshin JA, et al
    The Relationships between Markers of Tubular Injury and Intrarenal Hemodynamic Function in Adults with and without Type 1 Diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Oct 12. doi: 10.1111/dom.13556.
    PubMed     Text format     Abstract available


  3. CHO KYG, Nakamura A, Omori K, Takase T, et al
    Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type-2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial.
    Diabetes Obes Metab. 2018 Oct 12. doi: 10.1111/dom.13557.
    PubMed     Text format     Abstract available


  4. BAIN SC, Mosenzon O, Arechavaleta R, Bogdanski P, et al
    Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
    Diabetes Obes Metab. 2018 Oct 4. doi: 10.1111/dom.13553.
    PubMed     Text format     Abstract available


  5. GARCIA-FINANA M, Hughes DM, Cheyne CP, Broadbent DM, et al
    Personalized risk-based screening for diabetic retinopathy: a multivariate approach vs. the use of stratification rules.
    Diabetes Obes Metab. 2018 Oct 3. doi: 10.1111/dom.13552.
    PubMed     Text format     Abstract available


  6. MAGALHAES JP, Judice PB, Ribeiro R, Andrade R, et al
    Effectiveness of high intensity interval training combined with resistance training vs. continuous moderate intensity training combined with resistance training in patients with type 2 diabetes - 1 year randomized controlled trial.
    Diabetes Obes Metab. 2018 Oct 3. doi: 10.1111/dom.13551.
    PubMed     Text format     Abstract available


  7. PEARCE I, Simo R, Lovestam-Adrian M, Wong DT, et al
    Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review.
    Diabetes Obes Metab. 2018 Oct 2. doi: 10.1111/dom.13550.
    PubMed     Text format     Abstract available


  8. MULDER S, Hamidi H, Kretzler M, Ju W, et al
    An integrative systems biology approach for precision medicine in diabetic kidney disease.
    Diabetes Obes Metab. 2018;20 Suppl 3:6-13.
    PubMed     Text format     Abstract available


  9. DE VRIES JK, Levin A, Loud F, Adler A, et al
    Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives.
    Diabetes Obes Metab. 2018;20 Suppl 3:24-29.
    PubMed     Text format     Abstract available


  10. MOL PGM, Thompson A, Heerspink HJL, Leufkens HGM, et al
    Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.
    Diabetes Obes Metab. 2018;20 Suppl 3:19-23.
    PubMed     Text format     Abstract available


  11. HEERSPINK HJL, de Zeeuw D
    Treating diabetic complications; from large randomized clinical trials to precision medicine.
    Diabetes Obes Metab. 2018;20 Suppl 3:3-5.
    PubMed     Text format     Abstract available


    September 2018
  12. AL-QAISSI A, Papageorgiou M, Deshmukh H, Madden LA, et al
    The effects of acute insulin-induced hypoglycaemia on endothelial microparticles in adults with and without type 2 diabetes.
    Diabetes Obes Metab. 2018 Sep 28. doi: 10.1111/dom.13548.
    PubMed     Text format     Abstract available


  13. NAUCK MA, Buse JB, Mann JFE, Pocock S, et al
    Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.
    Diabetes Obes Metab. 2018 Sep 27. doi: 10.1111/dom.13547.
    PubMed     Text format     Abstract available


  14. BUSE JB, Carlson AL, Komatsu M, Mosenzon O, et al
    Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial.
    Diabetes Obes Metab. 2018 Sep 26. doi: 10.1111/dom.13545.
    PubMed     Text format     Abstract available


  15. LIAKOS A, Lambadiari V, Bargiota A, Kitsios K, et al
    Effect of liraglutide on ambulatory blood pressure in hypertensive patients with type 2 diabetes: randomized, double blind, placebo-controlled trial.
    Diabetes Obes Metab. 2018 Sep 22. doi: 10.1111/dom.13541.
    PubMed     Text format     Abstract available


  16. BAIN SC, Klufas MA, Ho A, Matthews DR, et al
    Worsening diabetic retinopathy with rapid improvement in systemic glucose control: a review.
    Diabetes Obes Metab. 2018 Sep 18. doi: 10.1111/dom.13538.
    PubMed     Text format     Abstract available


  17. SEUFERT J, Fritsche A, Pscherer S, Anderten H, et al
    Titration and optimization trial for the initiation of insulin glargine 100 U/mL in inadequately controlled type-2 diabetes patients on oral antidiabetic drugs.
    Diabetes Obes Metab. 2018 Sep 18. doi: 10.1111/dom.13535.
    PubMed     Text format     Abstract available


  18. ABDURRACHIM D, Teo XQ, Woo CC, Chan WX, et al
    Empagliflozin lowers myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized (13) C magnetic resonance spectroscopy study.
    Diabetes Obes Metab. 2018 Sep 17. doi: 10.1111/dom.13536.
    PubMed     Text format     Abstract available


  19. NICHOLS GA, Philip S, Reynolds K, Granowitz CB, et al
    Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin-Controlled LDL Cholesterol.
    Diabetes Obes Metab. 2018 Sep 17. doi: 10.1111/dom.13537.
    PubMed     Text format     Abstract available


  20. MOSER O, Eckstein ML, Mueller A, Birnbaumer P, et al
    Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: a randomised cross-over trial.
    Diabetes Obes Metab. 2018 Sep 17. doi: 10.1111/dom.13534.
    PubMed     Text format     Abstract available


  21. KUO S, Yang CT, Wu JS, Ou HT, et al
    Effects of intensifying triple oral antidiabetic drug therapy by initiating insulin versus enhancing oral antidiabetic drug therapy on clinical outcomes in patients with type 2 diabetes: a nationwide population-based, propensity score-matched cohort s
    Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13525.
    PubMed     Text format     Abstract available


  22. SINGH RG, Nguyen NN, DeSouza SV, Pendharkar SA, et al
    Comprehensive analysis of body composition and insulin traits associated with intra-pancreatic fat deposition in health and new-onset prediabetes/diabetes after acute pancreatitis.
    Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13523.
    PubMed     Text format     Abstract available


  23. YOSHIKAWA F, Kumashiro N, Shigiyama F, Uchino H, et al
    Efficacy of Intermittent Empagliflozin Supplementation on Dietary Self-Management and Glycemic Control in Patients With Poorly Controlled Type 2 Diabetes: A 24-Week Randomized Controlled Trial.
    Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13524.
    PubMed     Text format     Abstract available


  24. SHIMIZU M, Suzuki K, Kato K, Jojima T, et al
    Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13520.
    PubMed     Text format     Abstract available


  25. YU M, Shankar RR, Zhang R, Zhang Y, et al
    Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with pre-mixed insulin.
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13517.
    PubMed     Text format     Abstract available


  26. NATALI A, Nesti L, Venturi E, Shore AC, et al
    Metformin is the key factor for elevated plasma GDF-15 levels in type 2 diabetes: a nested, case-control study.
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13519.
    PubMed     Text format     Abstract available


  27. KHUNTI K, Seidu S, Davies MJ
    Should sodium glucose co-transporter 2 inhibitors be considered as first line oral therapy for people with type 2 diabetes?
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13518.
    PubMed     Text format     Abstract available


  28. IDRIS I
    News and Views for September 2018: Highlights from the American Diabetes Association Scientific meeting, June 2018.
    Diabetes Obes Metab. 2018;20:2321-2324.
    PubMed     Text format    


  29. RIAHI Y, Israeli T, Cerasi E, Leibowitz G, et al
    Effects of proinsulin misfolding on beta-cell dynamics, differentiation and function in diabetes.
    Diabetes Obes Metab. 2018;20 Suppl 2:95-103.
    PubMed     Text format     Abstract available


  30. FOLLI F, La Rosa S, Finzi G, Davalli AM, et al
    Pancreatic islet of Langerhans' cytoarchitecture and ultrastructure in normal glucose tolerance and in type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018;20 Suppl 2:137-144.
    PubMed     Text format     Abstract available


    August 2018
  31. BOLLI GB, Wysham C, Fisher M, Chevalier S, et al
    A post hoc pooled analysis to evaluate hypoglycaemia risk with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in people with type 2 diabetes on a basal-only insulin regimen.
    Diabetes Obes Metab. 2018 Aug 29. doi: 10.1111/dom.13515.
    PubMed     Text format     Abstract available


  32. GRANADOS A, Gebremariam A, Gidding SS, Terry JG, et al
    Association of Abdominal Muscle Composition with Prediabetes and Diabetes: The CARDIA Study.
    Diabetes Obes Metab. 2018 Aug 29. doi: 10.1111/dom.13513.
    PubMed     Text format     Abstract available


  33. YU E, Ruiz-Canela M, Razquin C, Guasch-Ferre M, et al
    Changes in Arginine are Inversely Associated with Type 2 Diabetes: A Case-Cohort Study in the PREDIMED Trial.
    Diabetes Obes Metab. 2018 Aug 26. doi: 10.1111/dom.13514.
    PubMed     Text format     Abstract available


  34. BELL DSH, Goncalves E
    Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies.
    Diabetes Obes Metab. 2018 Aug 24. doi: 10.1111/dom.13512.
    PubMed     Text format     Abstract available


  35. RYAN PB, Rosenthal N
    Comment on Ryan, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 ob
    Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13509.
    PubMed     Text format     Abstract available


  36. ARNOLD SV, Seman L, Tang F, Peri-Okonny PA, et al
    Real-World Opportunity of Empagliflozin to Improve Blood Pressure Control in African Americans with Type 2 Diabetes: An NCDR(R) "Research-to-Practice" Project From the Diabetes Collaborative Registry (DCR).
    Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13510.
    PubMed     Text format     Abstract available


  37. ARNOLD SV, Yap J, Lam CSP, Tang F, et al
    Management of patients with diabetes and heart failure with reduced ejection fraction: an international comparison.
    Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13511.
    PubMed     Text format     Abstract available


  38. DORIS J, Millar SA, Idris I, O'Sullivan SE, et al
    Genetic Polymorphisms of the Endocannabinoid System in Obesity and Diabetes.
    Diabetes Obes Metab. 2018 Aug 21. doi: 10.1111/dom.13504.
    PubMed     Text format     Abstract available


  39. GARIANI K, Lebowitz D, von Dach E, Kressmann B, et al
    Remission in Diabetic Foot Infections: Duration of Antibiotic Therapy and Other Possible Associated Factors.
    Diabetes Obes Metab. 2018 Aug 21. doi: 10.1111/dom.13507.
    PubMed     Text format     Abstract available


  40. WANG W, Ruiz LN, Filippova E, Song KH, et al
    Efficacy and Safety of Once-weekly Dulaglutide Versus Insulin Glargine in Mainly Asian Patients with Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea: a 52-week Open-label, Randomized Phase 3 Trial.
    Diabetes Obes Metab. 2018 Aug 21. doi: 10.1111/dom.13506.
    PubMed     Text format     Abstract available


  41. BLEVINS TC, Barve A, Sun B, Raiter Y, et al
    Efficacy and Safety of MYL-1501D Versus Insulin Glargine in Patients With Type 2 Diabetes After 24 Weeks: Results of the Phase 3 INSTRIDE 2 Study.
    Diabetes Obes Metab. 2018 Aug 15. doi: 10.1111/dom.13495.
    PubMed     Text format     Abstract available


  42. PARKER ED, Wittbrodt ET, McPheeters JT, Frias JP, et al
    Comparison of Healthcare Resource Utilization and Costs in Type 2 Diabetes Patients Initiating Dapagliflozin versus Sitagliptin.
    Diabetes Obes Metab. 2018 Aug 12. doi: 10.1111/dom.13502.
    PubMed     Text format     Abstract available


  43. KORSMO-HAUGEN HK, Brurberg KG, Mann J, Aas AM, et al
    Carbohydrate quantity in the dietary management of type 2 diabetes - a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Aug 11. doi: 10.1111/dom.13499.
    PubMed     Text format     Abstract available


  44. KAKU K, Haneda M, Tanaka Y, Lee G, et al
    Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2018 Aug 9. doi: 10.1111/dom.13496.
    PubMed     Text format     Abstract available


  45. CHEN HF, Ho CA, Li CY
    Risk of heart failure in type 2 diabetes population: Comparison with non-diabetes subjects with and without coronary heart diseases.
    Diabetes Obes Metab. 2018 Aug 8. doi: 10.1111/dom.13493.
    PubMed     Text format     Abstract available


  46. BAILEY CJ, Marx N
    Cardiovascular protection in type 2 diabetes: insights from recent outcome trials.
    Diabetes Obes Metab. 2018 Aug 8. doi: 10.1111/dom.13492.
    PubMed     Text format     Abstract available


  47. CHRISTENSEN P, Meinert Larsen T, Westerterp-Plantenga M, Macdonald I, et al
    Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW).
    Diabetes Obes Metab. 2018 Aug 7. doi: 10.1111/dom.13466.
    PubMed     Text format     Abstract available


  48. ELBAZ-GREENER G, Bloch O, Kumets I, Blatt A, et al
    Endogenous GLP-1 system response is impaired during St-elevation myocardial infarction in type 2 diabetes patients.
    Diabetes Obes Metab. 2018 Aug 6. doi: 10.1111/dom.13490.
    PubMed     Text format     Abstract available


  49. BAE JC, Min KW, Kim YH, Kim KA, et al
    Efficacy and safety of fixed-dose comBination therApy with gemigLiptin (50 mg) and rosuvAstatiN (20 mg) Compared with Each monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, p
    Diabetes Obes Metab. 2018 Aug 6. doi: 10.1111/dom.13491.
    PubMed     Text format     Abstract available


  50. MATIKAINEN N, Soderlund S, Bjornson E, Pietilainen K, et al
    Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomised controlled study.
    Diabetes Obes Metab. 2018 Aug 2. doi: 10.1111/dom.13487.
    PubMed     Text format     Abstract available


  51. NEYMAN A, Nelson J, Tersey S, Mirmira RG, et al
    Persistent Elevations in Circulating INS DNA Among Subjects with Longstanding Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Aug 2. doi: 10.1111/dom.13489.
    PubMed     Text format     Abstract available


  52. OUCHI M, Oba K, Suganami H, Yoshida A, et al
    This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated".
    Diabetes Obes Metab. 2018;20:2041-2042.
    PubMed     Text format    


    July 2018
  53. LIAN J, McGhee SM, So C, Chau J, et al
    Long-term cost-effectiveness of Patient Empowerment Programme for Type 2 Diabetes Mellitus in primary care.
    Diabetes Obes Metab. 2018 Jul 29. doi: 10.1111/dom.13485.
    PubMed     Text format     Abstract available


  54. AVGERINOS I, Karagiannis T, Malandris K, Liakos A, et al
    Glucagon-like peptide 1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Jul 29. doi: 10.1111/dom.13484.
    PubMed     Text format     Abstract available


  55. RENARD E, Tubiana-Rufi N, Bonnemaison-Gilbert E, Coutant R, et al
    Closed-Loop Driven by Control-to-Range Algorithm Outperforms Threshold-Low-Glucose-Suspend Insulin Delivery on Glucose Control Albeit not on Nocturnal Hypoglycemia in Pre-pubertal Patients with Type 1 Diabetes in Supervised Hotel Setting.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13482.
    PubMed     Text format     Abstract available


  56. MOTTALIB A, Tomah S, Hafida S, Elseaidy T, et al
    Intensive Multidisciplinary Weight Management in Patients with Type 1 Diabetes and Obesity: a 1-Year Retrospective Matched Cohort Study.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13478.
    PubMed     Text format     Abstract available


  57. SCHMEDT N, Andersohn F, Walker J, Garbe E, et al
    Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: a nested case-control study.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13480.
    PubMed     Text format    


  58. TANG H, Yang K, Song Y, Han J, et al
    Meta-analysis of the association between sodium-glucose cotransporter 2 inhibitors and risk of skin cancer among patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13474.
    PubMed     Text format     Abstract available


  59. KU EJ, Lee DH, Jeon HJ, Oh TK, et al
    Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: an observational study in clinical practice.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13476.
    PubMed     Text format     Abstract available


  60. DAWWAS GK, Smith SM, Park H
    Cardiovascular Outcomes of Sodium Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13477.
    PubMed     Text format     Abstract available


  61. SCOTT R, Morgan J, Zimmer Z, Lam RLH, et al
    A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study.
    Diabetes Obes Metab. 2018 Jul 18. doi: 10.1111/dom.13473.
    PubMed     Text format     Abstract available


  62. BRUCE DG, Davis WA, Davis TM
    Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II.
    Diabetes Obes Metab. 2018 Jul 13. doi: 10.1111/dom.13469.
    PubMed     Text format     Abstract available


  63. JAVIER ESCALADA F, Halimi S, Senior PA, Bonnemaire M, et al
    Glycemic control and hypoglycemia benefits with insulin glargine 300 U/mL (Gla-300) extend to people with type 2 diabetes and mild-to-moderate renal impairment.
    Diabetes Obes Metab. 2018 Jul 13. doi: 10.1111/dom.13470.
    PubMed     Text format     Abstract available


  64. IDZERDA NMA, Persson F, Pena MJ, Brenner BM, et al
    NT-proBNP predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.
    Diabetes Obes Metab. 2018 Jul 10. doi: 10.1111/dom.13465.
    PubMed     Text format     Abstract available


  65. KADOWAKI T, Sarai N, Hirakawa T, Taki K, et al
    Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics, and severity of renal impairment: A Japanese database analysis.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13463.
    PubMed     Text format    


  66. ROSENSTOCK J, Handelsman Y, Vidal J, Ampudia Blasco FJ, et al
    Propensity score-matched comparative analyses of simultaneously administered fixed-ratio iGlarLixi (LixiLan) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13462.
    PubMed     Text format     Abstract available


  67. WANG JL, Dong YH, Ko WC, Chang CH, et al
    Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: a population-based cohort study.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13461.
    PubMed     Text format     Abstract available


  68. HARJUTSALO V, Thomas MC, Forsblom C, Groop PH, et al
    Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes.
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13456.
    PubMed     Text format     Abstract available


  69. RIDDERSTRALE M, Rosenstock J, Andersen KR, Woerle HJ, et al
    Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13457.
    PubMed     Text format     Abstract available


  70. GUO L, Chen L, Chang B, Yang L, et al
    A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13454.
    PubMed     Text format     Abstract available


    June 2018
  71. ZULLO AR, Hersey M, Lee Y, Sharmin S, et al
    Outcomes of "Diabetes-Friendly" versus "Diabetes-Unfriendly" Beta-blockers in Older Nursing Home Residents with Diabetes after Acute Myocardial Infarction.
    Diabetes Obes Metab. 2018 Jun 28. doi: 10.1111/dom.13451.
    PubMed     Text format     Abstract available


  72. MULLER-WIELAND D, Kellerer M, Cypryk K, Skripova D, et al
    Efficacy and Safety of Dapagliflozin or Dapagliflozin Plus Saxagliptin Versus Glimepiride as Add-on to Metformin in Patients With Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jun 27. doi: 10.1111/dom.13437.
    PubMed     Text format     Abstract available


  73. FRIER BM, Landgraf W, Zhang M, Bolli GB, et al
    Hypoglycaemia risk in the first eight weeks of titration with insulin glargine 100 U/mL in previously insulin-naive people with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13450.
    PubMed     Text format     Abstract available


  74. SPILLER S, Bluher M, Hoffmann R
    Plasma levels of free fatty acids correlate with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13449.
    PubMed     Text format     Abstract available


  75. SULLIVAN SD, Bailey TS, Roussel R, Zhou FL, et al
    Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13345.
    PubMed     Text format     Abstract available


  76. RYAN PB, Buse JB, Schuemie MJ, DeFalco F, et al
    Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (O
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13424.
    PubMed     Text format     Abstract available


  77. WEIR DL, Abrahamowicz M, Beauchamp ME, Eurich DT, et al
    Acute vs Cumulative Benefits of Metformin use in Patients with Type 2 Diabetes and Heart Failure.
    Diabetes Obes Metab. 2018 Jun 23. doi: 10.1111/dom.13448.
    PubMed     Text format     Abstract available


  78. STEPHENSON JJ, Raval AD, Kern DM, Bae JP, et al
    Nonadherence to Basal Insulin Among Patients With Type 2 Diabetes in a US Managed Care Population: Results from a Patient Survey.
    Diabetes Obes Metab. 2018 Jun 21. doi: 10.1111/dom.13446.
    PubMed     Text format     Abstract available


  79. SUGIMOTO DH, Dex T, Stager W, Aroda VR, et al
    Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as high and low risk according to HEDIS measures.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13438.
    PubMed     Text format     Abstract available


  80. ALFREDSSON J, Green JB, Stevens SR, Reed SD, et al
    Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13377.
    PubMed     Text format     Abstract available


  81. MELMER A, Kempf P, Lunger L, Pieber TR, et al
    Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion, and ketogenesis in type 1 diabetes - a randomized, placebo-controlled, double blind, cross-over pilot study.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13439.
    PubMed     Text format     Abstract available


  82. JAIKUMKAO K, Pongchaidecha A, Chueakula N, Thongnak LO, et al
    Dapagliflozin, a SGLT2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, ER stress, and apoptosis in pre-diabetic rats.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13441.
    PubMed     Text format     Abstract available


  83. ANDERSEN G, Meiffren G, Lamers D, DeVries JH, et al
    Ultra-rapid BioChaperone Lispro Improves post-prandial Blood Glucose Excursions versus Insulin Lispro in a 14-day crossover Treatment Study in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13442.
    PubMed     Text format     Abstract available


  84. KAZIERAD DJ, Chidsey K, Somayaji VR, Bergman AJ, et al
    Efficacy and Safety of the Glucagon Receptor Antagonist PF-06291874: A 12-Week, Randomized, Dose-Response Study in Patients With Type 2 Diabetes Mellitus on Background Metformin Therapy.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13440.
    PubMed     Text format     Abstract available


  85. YAN Z, Shyr ZA, Fortunato M, Welscher A, et al
    High Fat Diet induced Remission of Diabetes in a subset of KATP -GOF Insulin Secretory-Deficient mice.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13423.
    PubMed     Text format     Abstract available


  86. KORSATKO S, Jensen L, Brunner M, Sach-Friedl S, et al
    Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in subjects with type 2 diabetes: a randomised, placebo-controlled, double-blind, crossover trial.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13422.
    PubMed     Text format     Abstract available


  87. RABBONE I, Minuto N, Toni S, Lombardo F, et al
    Insulin pump breakdown and infusion set failure in Italian children with type 1 diabetes: 1-year prospective observational study with suggestions to minimize clinical impact.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13419.
    PubMed     Text format     Abstract available


  88. TSURUTANI Y, Nakai K, Inoue K, Kosuke A, et al
    Comparative study of ipragliflozin with sitagliptin on multiple metabolic changes in Japanese patients with type 2 diabetes: a multicenter, randomized, prospective, open-label, active-controlled study.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13421.
    PubMed     Text format     Abstract available


  89. FIORETTO P, Del Prato S, Buse JB, Goldenberg R, et al
    Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes and Moderate Renal Impairment (Chronic Kidney Disease Stage 3A): The DERIVE Study.
    Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13413.
    PubMed     Text format     Abstract available


  90. TERAUCHI Y, Riddle MC, Hirose T, Koyama M, et al
    Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: a 12-month comparison by concomitant sulphonylurea and/or glinide use.
    Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13414.
    PubMed     Text format     Abstract available


  91. EMANUEL AL, de Clercq NC, Koopen AM, van Poelgeest E, et al
    Iloprost infusion prevents the insulin-induced reduction in skeletal muscle microvascular blood volume but does not enhance peripheral glucose uptake in type 2 diabetic patients.
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13410.
    PubMed     Text format     Abstract available


  92. NIMRI R, Dassau E, Segall T, Muller I, et al
    Adjusting insulin doses in patients with type 1 diabetes that use insulin pump and continuous glucose monitoring - Variations among countries and physicians.
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13408.
    PubMed     Text format     Abstract available


  93. FARR OM, Mantzoros CS
    Obese individuals with type 2 diabetes demonstrate decreased activation of the salience-related insula and increased activation of the emotion/salience-related amygdala to visual food cues compared to non-obese individuals with diabetes: a preliminary
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13403.
    PubMed     Text format     Abstract available


  94. REZNIK Y, Habteab A, Castaneda J, Shin J, et al
    Contribution of basal and postprandial hyperglycemia in type 2 diabetes patients treated by an intensified insulin regimen: impact of pump therapy in the OPT2MISE trial.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13398.
    PubMed     Text format     Abstract available


  95. HANS DEVRIES J, Desouza C, Bellary S, Unger J, et al
    Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13396.
    PubMed     Text format     Abstract available


  96. HAN KA, Chon S, Chung CH, Lim S, et al
    Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: a randomized controlled trial.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13394.
    PubMed     Text format     Abstract available


  97. KAKU K, Kuroda S, Ishida K, Umeda Y, et al
    Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: results from a randomized, phase IV study.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13397.
    PubMed     Text format     Abstract available


  98. JALVING AC, Gant CM, Binnenmars SH, Soedamah-Muthu SS, et al
    Glycemic Control In The Diabetes And Lifestyle Cohort Twente - A Cross-Sectional Assessment Of Lifestyle And Pharmacological Management On Hba1c Target Achievement.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13399.
    PubMed     Text format     Abstract available


  99. KREBS JD, Arahill J, Cresswell P, Weatherall M, et al
    The effect of additional mealtime insulin bolus using an insulin-to-protein ratio compared to to usual carbohydrate counting on postprandial glucose in those with Type 1 diabetes who usually follow a carbohydrate-restricted diet: a randomised cross-ov
    Diabetes Obes Metab. 2018 Jun 1. doi: 10.1111/dom.13392.
    PubMed     Text format     Abstract available


    May 2018
  100. GANDA OP, Plutzky J, Sanganalmath SK, Bujas-Bobanovic M, et al
    Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.
    Diabetes Obes Metab. 2018 May 26. doi: 10.1111/dom.13384.
    PubMed     Text format     Abstract available


  101. NORONHA JC, Braunstein CR, Glenn A, Khan TA, et al
    Effect of Small Doses of Fructose and Allulose on Postprandial Glucose Metabolism in Type 2 Diabetes: A Double-blind, Randomized, Controlled, Acute Feeding Equivalence Trial.
    Diabetes Obes Metab. 2018 May 24. doi: 10.1111/dom.13374.
    PubMed     Text format     Abstract available


  102. DRUMMOND RS, Malkin S, Du Preez M, Lee XY, et al
    Management of type 2 diabetes with Fixed-Ratio combination insulin degludec/liraglutide (IDEGLIRA) versus Basal-Bolus therapy (INSULIN GLARGINE U100 PLUS INSULIN ASPART): A Short-Term Cost-Effectiveness analysis in the UK setting.
    Diabetes Obes Metab. 2018 May 24. doi: 10.1111/dom.13375.
    PubMed     Text format     Abstract available


  103. CAO B, Rosenblat JD, Brietzke E, Park C, et al
    Comparative Efficacy and Acceptability of Anti-Diabetic Agents for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Network Meta-analysis.
    Diabetes Obes Metab. 2018 May 23. doi: 10.1111/dom.13373.
    PubMed     Text format     Abstract available


  104. KAWASAKI R, Konta T, Nishida K
    Lipid-lowering medication use is associated with decreased risk of diabetic retinopathy and its treatments in patients with type 2 diabetes: a real-world observational analysis of a health claims database.
    Diabetes Obes Metab. 2018 May 22. doi: 10.1111/dom.13372.
    PubMed     Text format     Abstract available


  105. BELL DSH, Goncalves E
    Should we still be utilizing warfarin in the type 2 diabetic patient?
    Diabetes Obes Metab. 2018 May 22. doi: 10.1111/dom.13371.
    PubMed     Text format     Abstract available


  106. LESLIE RD, Pozzilli P, Peters AL, Buzzetti R, et al
    Response to the comment on Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2,-4 and -5 Trials.
    Diabetes Obes Metab. 2018 May 20. doi: 10.1111/dom.13366.
    PubMed     Text format     Abstract available


  107. SUZUKI R, Eiki JI, Moritoyo T, Furihata K, et al
    Effect of Short Term Treatment with Sitagliptin or Glibenclamide on Daily Glucose Fluctuation in Drug-naive Japanese Patients with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 May 17. doi: 10.1111/dom.13364.
    PubMed     Text format     Abstract available


  108. KAWAMORI R, Haneda M, Suzaki K, Cheng G, et al
    Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13352.
    PubMed     Text format     Abstract available


  109. HOME PD, Lam RLH, Carofano WL, Golm GT, et al
    Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: a randomized, open-label clinical trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13354.
    PubMed     Text format     Abstract available


  110. AHREN B, Atkin SL, Charpentier G, Warren ML, et al
    Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in SUSTAIN 1-5 trials.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13353.
    PubMed     Text format     Abstract available


  111. SHIMADA A, Hanafusa T, Yasui A, Lee G, et al
    Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13351.
    PubMed     Text format     Abstract available


  112. HOLLANDER PA, Carofano WL, Lam RLH, Golm GT, et al
    Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: a randomized, open-label clinical trial.
    Diabetes Obes Metab. 2018 May 14. doi: 10.1111/dom.13363.
    PubMed     Text format     Abstract available


  113. ANDREADIS P, Karagiannis T, Malandris K, Avgerinos I, et al
    Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 May 13. doi: 10.1111/dom.13361.
    PubMed     Text format     Abstract available


  114. BAILEY CJ
    European Medicines Agency: approval of new glucose-lowering medicines for type 2 diabetes.
    Diabetes Obes Metab. 2018 May 13. doi: 10.1111/dom.13360.
    PubMed     Text format     Abstract available


  115. PETRI KCC, Ingwersen SH, Flint A, Zacho J, et al
    Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes.
    Diabetes Obes Metab. 2018 May 11. doi: 10.1111/dom.13358.
    PubMed     Text format     Abstract available


  116. CURTIN F, Bernard C, Levet S, Perron H, et al
    A new therapeutic approach for type 1 diabetes: rationale for GNbAC1 an anti-HERV-W-Env monoclonal antibody.
    Diabetes Obes Metab. 2018 May 10. doi: 10.1111/dom.13357.
    PubMed     Text format     Abstract available


  117. BLIND E, Janssen H, Dunder K, de Graeff PA, et al
    The European Medicines Agency's Approval of New Medicines for Type 2 Diabetes.
    Diabetes Obes Metab. 2018 May 8. doi: 10.1111/dom.13349.
    PubMed     Text format     Abstract available


  118. FITZPATRICK C, Chatterjee S, Seidu S, Bodicoat DH, et al
    Association of hypoglycaemia and cardiac arrhythmia risk in patients with diabetes mellitus: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 May 8. doi: 10.1111/dom.13348.
    PubMed     Text format     Abstract available


  119. CURTIS HJ, Dennis JM, Shields BM, Walker AJ, et al
    Time Trends and Geographical Variation in Prescribing of Drugs for Diabetes in England 1998-2017.
    Diabetes Obes Metab. 2018 May 7. doi: 10.1111/dom.13346.
    PubMed     Text format     Abstract available


  120. MAIORINO MI, Chiodini P, Bellastella G, Scappaticcio L, et al
    Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2018 May 7. doi: 10.1111/dom.13343.
    PubMed     Text format     Abstract available


  121. OVERBEEK J, Heintjes E, Huisman E, Tikkanen C, et al
    Clinical Effectiveness of Liraglutide versus Basal Insulin in a Real-world Setting: Evidence for Improved Glycaemic and Weight Control in Obese Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2018 May 3. doi: 10.1111/dom.13335.
    PubMed     Text format     Abstract available


  122. HUANG CJ, Wang WT, Sung SH, Chen CH, et al
    Blood Glucose Reduction by Diabetic Drugs with Minimal Hypoglycemia Risk for Cardiovascular Outcomes: Evidence from Meta-regression Analysis of Randomized Controlled Trials.
    Diabetes Obes Metab. 2018 May 2. doi: 10.1111/dom.13342.
    PubMed     Text format     Abstract available


    April 2018
  123. CHEN YH, Huang CN, Cho YM, Li P, et al
    Efficacy and safety of dulaglutide monotherapy compared to glimepiride in East Asian patients with type 2 diabetes in a multicenter, double-blind, randomized, parallel-arm, active comparator, phase 3 trial.
    Diabetes Obes Metab. 2018 Apr 30. doi: 10.1111/dom.13340.
    PubMed     Text format     Abstract available


  124. GOLDENBERG RM, Assimakopoulos P, Gilbert JD, Gottesman IS, et al
    A Practical Approach and Algorithm for Intensifying Beyond Basal Insulin in Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Apr 29. doi: 10.1111/dom.13337.
    PubMed     Text format     Abstract available


  125. ZHU XX, Zhu DL, Li XY, Li YL, et al
    Dorzagliatin (HMS5552), a Novel Dual Acting Glucokinase Activator, Improves Glycemic Control and Pancreatic beta-cell Function in Patients with Type 2 Diabetes: A 28-day Treatment Study Using Biomarker-Guided Patient Selection.
    Diabetes Obes Metab. 2018 Apr 29. doi: 10.1111/dom.13338.
    PubMed     Text format     Abstract available


  126. PANDEYA N, Huxley RR, Chung HF, Dobson AJ, et al
    Female reproductive history and risk of type 2 diabetes: a prospective analysis of 126,721 women.
    Diabetes Obes Metab. 2018 Apr 25. doi: 10.1111/dom.13336.
    PubMed     Text format     Abstract available


  127. WARREN M, Chaykin L, Trachtenbarg D, Nayak G, et al
    Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1-5 trials.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13331.
    PubMed     Text format     Abstract available


  128. LIU DM, Mosialou I, Liu JM
    Bone: another potential target to treat, prevent and predict diabetes.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13330.
    PubMed     Text format     Abstract available


  129. COLLIER A, Connelly PJ, Hair M, Cameron L, et al
    Mortality risk is still higher in people with type 1 diabetes: a population-based cohort study (The Ayrshirre Diabetes fOllow-up Cohort (ADOC) study).
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13334.
    PubMed     Text format     Abstract available


  130. SIDORENKOV G, van Boven JFM, Hoekstra T, Nijpels G, et al
    HbA1c response after insulin initiation in patients with type 2 diabetes in real-life: identifying distinct subgroups.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13332.
    PubMed     Text format     Abstract available


  131. OUT M, Top WMC, Lehert P, Schalkwijk CA, et al
    Long-term treatment with metformin in type 2 diabetes and vitamin D levels: A post hoc analysis of a randomised placebo-controlled trial.
    Diabetes Obes Metab. 2018 Apr 17. doi: 10.1111/dom.13327.
    PubMed     Text format    


  132. BLEVINS TC, Barve A, Sun B, Ankersen M, et al
    Efficacy and Safety of MYL-1501D Versus Insulin Glargine in Patients With Type 1 Diabetes After 52 Weeks: Results of the Phase 3 INSTRIDE 1 Study.
    Diabetes Obes Metab. 2018 Apr 15. doi: 10.1111/dom.13322.
    PubMed     Text format     Abstract available


  133. ANDERSEN ES, Lund A, Bagger JI, Andreasen C, et al
    Is glucagon-like peptide-1 fully protected by dipeptidyl peptidase 4 inhibitor administration in patients with type 2 diabetes?
    Diabetes Obes Metab. 2018 Apr 14. doi: 10.1111/dom.13321.
    PubMed     Text format     Abstract available


  134. PONTIROLI AE, Ceriani V
    Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality?
    Diabetes Obes Metab. 2018 Apr 13. doi: 10.1111/dom.13317.
    PubMed     Text format     Abstract available


  135. BARNETT AH, Arnoldini S, Hunt B, Subramanian G, et al
    Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A Long-Term Cost-Effectiveness analysis.
    Diabetes Obes Metab. 2018 Apr 13. doi: 10.1111/dom.13318.
    PubMed     Text format     Abstract available


  136. FARNGREN J, Persson M, Ahren B
    Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes-a randomized, placebo-controlled study.
    Diabetes Obes Metab. 2018 Apr 12. doi: 10.1111/dom.13316.
    PubMed     Text format     Abstract available


    March 2018
  137. HEERSPINK HJL, Andress DL, Bakris G, Brennan JJ, et al
    Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial.
    Diabetes Obes Metab. 2018 Mar 31. doi: 10.1111/dom.13315.
    PubMed     Text format     Abstract available


  138. MATHIEU C, Del Prato S, Botros FT, Thieu VT, et al
    Effect of Once Weekly Dulaglutide by Baseline Beta-cell Function in People with Type 2 Diabetes in the AWARD Programme.
    Diabetes Obes Metab. 2018 Mar 30. doi: 10.1111/dom.13313.
    PubMed     Text format     Abstract available


  139. VOORMOLEN DN, DeVries JH, Sanson RME, Heringa MP, et al
    Continuous Glucose Monitoring during Diabetic Pregnancy (GlucoMOMS); a multicentre randomised controlled trial.
    Diabetes Obes Metab. 2018 Mar 30. doi: 10.1111/dom.13310.
    PubMed     Text format     Abstract available


  140. RADHOLM K, Chalmers J, Ohkuma T, Peters S, et al
    Use of the waist-to-height-ratio to predict cardiovascular risk in patients with diabetes: results from ADVANCE-ON.
    Diabetes Obes Metab. 2018 Mar 30. doi: 10.1111/dom.13311.
    PubMed     Text format     Abstract available


  141. BECKER RHA
    Comment to Heise, T, Norskov, M, Nosek, L, Kaplan, K, Famulla, S and Haahr, H. L. (2017), Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes. Diabetes Obes Met
    Diabetes Obes Metab. 2018 Mar 29. doi: 10.1111/dom.13308.
    PubMed     Text format     Abstract available


  142. HOU C, Xu Q, Diao S, Hewitt J, et al
    Mobile phone applications and self-management of diabetes: a systematic review with meta-analysis, meta-regression of 21 randomized trials, and GRADE.
    Diabetes Obes Metab. 2018 Mar 27. doi: 10.1111/dom.13307.
    PubMed     Text format     Abstract available


  143. ORSI E, Solini A, Bonora E, Fondelli C, et al
    Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Mar 26. doi: 10.1111/dom.13306.
    PubMed     Text format     Abstract available


  144. ARNOLD SV, Kosiborod M, Wang J, Fenici P, et al
    Burden of Cardio-Renal-Metabolic Conditions in Adults with Type 2 Diabetes within the Diabetes Collaborative Registry.
    Diabetes Obes Metab. 2018 Mar 25. doi: 10.1111/dom.13303.
    PubMed     Text format     Abstract available


  145. RUAN Y, Bally L, Thabit H, Leelarathna L, et al
    Hypoglycaemia Incidence and Recovery During Home Use of Hybrid Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Mar 25. doi: 10.1111/dom.13304.
    PubMed     Text format     Abstract available


  146. REED SD, Li Y, Leal J, Radican L, et al
    Longitudinal Medical Resources and Costs Among Type 2 Diabetes Patients Participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13292.
    PubMed     Text format     Abstract available


  147. FRIAS JP, Hardy E, Ahmed A, Ohman P, et al
    Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13296.
    PubMed     Text format     Abstract available


  148. GUO M, Ding J, Li J, Wang J, et al
    SGLT2 inhibitors and stroke risk in patients with type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13295.
    PubMed     Text format     Abstract available


  149. LI D, Shi W, Wang T, Tang H, et al
    SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13294.
    PubMed     Text format     Abstract available


  150. PICHE ME, Laberge AS, Brassard P, Arsenault BJ, et al
    Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: a 1 year randomized study.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13293.
    PubMed     Text format     Abstract available


  151. KIM YG, Jeon JY, Han SJ, Kim DJ, et al
    Sodium-glucose co-transporter 2 inhibitors and the risk for diabetic ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Diabetes Obes Metab. 2018 Mar 22. doi: 10.1111/dom.13297.
    PubMed     Text format     Abstract available


  152. MASTRACCI TL, Turatsinze JV, Book BK, Restrepo IA, et al
    Distinct Gene Expression Pathways in Islets from Individuals with Short- and Long-Duration Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Mar 22. doi: 10.1111/dom.13298.
    PubMed     Text format     Abstract available


  153. LAUBNER K, Riedel N, Fink K, Holl RW, et al
    Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus - a case control study.
    Diabetes Obes Metab. 2018 Mar 22. doi: 10.1111/dom.13300.
    PubMed     Text format     Abstract available


  154. YANG YS, Lim MH, Lee SO, Roh E, et al
    Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine.
    Diabetes Obes Metab. 2018 Mar 15. doi: 10.1111/dom.13282.
    PubMed     Text format     Abstract available


  155. JONES AG, McDonald TJ
    Comment on: Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
    Diabetes Obes Metab. 2018 Mar 14. doi: 10.1111/dom.13290.
    PubMed     Text format     Abstract available


  156. MONTVIDA O, Shaw J, Blonde L, Paul SK, et al
    Long-term sustainability of glycaemic achievements with second-line anti-diabetic therapies in patients with type 2 diabetes: A real-world study.
    Diabetes Obes Metab. 2018 Mar 14. doi: 10.1111/dom.13288.
    PubMed     Text format     Abstract available


  157. POP LM, Mari A, Zhao TJ, Mitchell L, et al
    Roux-en-Y Gastric Bypass Compared to Equivalent Diet Restriction: Mechanistic Insights into Diabetes Remission.
    Diabetes Obes Metab. 2018 Mar 13. doi: 10.1111/dom.13287.
    PubMed     Text format     Abstract available


  158. BRIL F, Millan L, Kalavalpalli S, McPhaul MJ, et al
    Use of a Metabolomic Approach to Non-invasively Diagnose Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Mar 12. doi: 10.1111/dom.13285.
    PubMed     Text format     Abstract available


  159. MOHANDAS C, Bonadonna R, Shojee-Moradie F, Jackson N, et al
    Ethnic differences in insulin secretory function between Black African and White European men with early type 2 diabetes.
    Diabetes Obes Metab. 2018 Mar 8. doi: 10.1111/dom.13283.
    PubMed     Text format     Abstract available


  160. JUNG HY, Kim B, Ji Y, Ryu HG, et al
    Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice.
    Diabetes Obes Metab. 2018 Mar 8. doi: 10.1111/dom.13284.
    PubMed     Text format     Abstract available


  161. SEAQUIST ER, Dulude H, Zhang XM, Rabasa-Lhoret R, et al
    A prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycemia in adults with type 1 diabetes in a real-world setting.
    Diabetes Obes Metab. 2018 Mar 5. doi: 10.1111/dom.13278.
    PubMed     Text format     Abstract available


  162. CEA-SORIANO L, Garcia-Rodriguez LA, Brodovicz KG, Masso Gonzalez E, et al
    Safety of Non-insulin glucose-lowering drugs in pregnant women with pre-gestational diabetes: a cohort study.
    Diabetes Obes Metab. 2018 Mar 2. doi: 10.1111/dom.13275.
    PubMed     Text format     Abstract available


  163. ALSALIM W, Persson M, Ahren B
    Different Glucagon Effects During DPP-4 Inhibition versus SGLT-2 Inhibition in Metformin-Treated Type 2 Diabetes Subjects.
    Diabetes Obes Metab. 2018 Mar 2. doi: 10.1111/dom.13276.
    PubMed     Text format     Abstract available


  164. BJORNSTAD P, Maahs DM, Roncal CA, Snell-Bergeon JK, et al
    Role of Bicarbonate Supplementation on Urine Uric Acid Crystals and Diabetic Tubulopathy in Adults with Type 1 Diabetes: A Brief Report.
    Diabetes Obes Metab. 2018 Mar 2. doi: 10.1111/dom.13274.
    PubMed     Text format     Abstract available


  165. HENRY RR, Muller-Wieland D, Taub PR, Bujas-Bobanovic M, et al
    Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome and without diabetes: Pooled data from 10 phase 3 trials.
    Diabetes Obes Metab. 2018 Mar 1. doi: 10.1111/dom.13273.
    PubMed     Text format     Abstract available


    February 2018
  166. HARASHIMA SI, Inagaki N, Kondo K, Maruyama N, et al
    Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: a 52-week, open-label, phase IV study.
    Diabetes Obes Metab. 2018 Feb 23. doi: 10.1111/dom.13267.
    PubMed     Text format     Abstract available


  167. GUJA C, Frias JP, Somogyi A, Jabbour S, et al
    Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study.
    Diabetes Obes Metab. 2018 Feb 23. doi: 10.1111/dom.13266.
    PubMed     Text format     Abstract available


  168. YAMADA T, Shojima N, Noma H, Yamauchi T, et al
    Sodium-glucose co-transporter 2 (SGLT2) inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2018 Feb 16. doi: 10.1111/dom.13260.
    PubMed     Text format     Abstract available


  169. HALUZIK M, Fulcher G, Pieber TR, Bardtrum L, et al
    Insulin degludec/insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia independent of baseline HbA1c levels, disease duration or BMI: A pooled meta-analysis of phase 3 studies in patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Feb 16. doi: 10.1111/dom.13261.
    PubMed     Text format     Abstract available


  170. JUNG CH, Rhee EJ, Lee WY, Min KW, et al
    A 52-week extension study of switching from gemigliptin vs. sitagliptin to gemigliptin only as an add-on to patients with type 2 diabetes inadequately controlled on metformin alone.
    Diabetes Obes Metab. 2018 Feb 13. doi: 10.1111/dom.13256.
    PubMed     Text format     Abstract available


  171. RAY KK, Leiter LA, Muller-Wieland D, Cariou B, et al
    Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
    Diabetes Obes Metab. 2018 Feb 13. doi: 10.1111/dom.13257.
    PubMed     Text format     Abstract available


  172. PANTALONE KM, Patel H, Yu M, Lando LF, et al
    Dulaglutide 1.5 mg as an Add-on Option for Patients Uncontrolled on Insulin: Subgroup Analysis by Age, Duration of Diabetes and Baseline HbA1c.
    Diabetes Obes Metab. 2018 Feb 12. doi: 10.1111/dom.13252.
    PubMed     Text format     Abstract available


  173. WONG CKH, Jiao F, Tang EHM, Tong T, et al
    Direct medical costs of diabetes mellitus in the year of mortality and year before mortality.
    Diabetes Obes Metab. 2018 Feb 12. doi: 10.1111/dom.13253.
    PubMed     Text format     Abstract available


  174. LAFFIN LJ, Bakris GL
    Results of ACCORDIAN in Accord with Lower Blood Pressure Begetting Lower Mortality in Patients with Diabetes.
    Diabetes Obes Metab. 2018 Feb 9. doi: 10.1111/dom.13249.
    PubMed     Text format     Abstract available


  175. BUCKLEY LF, Dixon DL, Wohlford GF 4th, Wijesinghe DS, et al
    Effect of Intensive Blood Pressure Control in Patients with Type 2 Diabetes Mellitus Over 9 Years of Follow-Up: A Subgroup Analysis of High-Risk ACCORDION Trial Participants.
    Diabetes Obes Metab. 2018 Feb 9. doi: 10.1111/dom.13248.
    PubMed     Text format     Abstract available


  176. BALDASSARRE MPA, Andersen A, Consoli A, Knop FK, et al
    Cardiovascular biomarkers in clinical studies of type 2 diabetes.
    Diabetes Obes Metab. 2018 Feb 8. doi: 10.1111/dom.13247.
    PubMed     Text format     Abstract available


  177. GORMSEN LC, Sondergaard E, Christensen NL, Jakobsen S, et al
    Metformin does not Affect Postabsorptive Hepatic Free Fatty Acid Uptake, Oxidation or Resecretion in Humans: A 3-months Placebo Controlled Clinical Trial in Patients with Type 2 Diabetes and Healthy Controls.
    Diabetes Obes Metab. 2018 Feb 6. doi: 10.1111/dom.13244.
    PubMed     Text format     Abstract available


  178. HEERSPINK HJL, Andress DL, Bakris G, Brennan JJ, et al
    Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
    Diabetes Obes Metab. 2018 Feb 6. doi: 10.1111/dom.13245.
    PubMed     Text format     Abstract available


  179. KHUNTI K, Kosiborod M, Ray KK
    Legacy benefits of blood glucose, blood pressure and lipid control in people with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?
    Diabetes Obes Metab. 2018 Feb 6. doi: 10.1111/dom.13243.
    PubMed     Text format     Abstract available


  180. MALMSTROM H, Walldius G, Carlsson S, Grill V, et al
    Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes - experience from the AMORIS study.
    Diabetes Obes Metab. 2018 Feb 5. doi: 10.1111/dom.13241.
    PubMed     Text format     Abstract available


  181. TRAN S, Retnakaran R, Zinman B, Kramer CK, et al
    Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
    Diabetes Obes Metab. 2018;20 Suppl 1:68-76.
    PubMed     Text format     Abstract available


  182. DANDONA P, Ghanim H, Chaudhuri A
    Incretins: Beyond type 2 diabetes.
    Diabetes Obes Metab. 2018;20 Suppl 1:59-67.
    PubMed     Text format     Abstract available


    January 2018
  183. THUESEN ACB, Vaag A
    Perspectives on diabetes mortality due to residual confounding and reverse causality by common disease.
    Diabetes Obes Metab. 2018 Jan 30. doi: 10.1111/dom.13238.
    PubMed     Text format     Abstract available


  184. POZZILLI P, Leslie RD, Peters AL, Buzzetti R, et al
    Dulaglutide Treatment Results in Effective Glycemic Control in Latent Autoimmune Diabetes in Adults (LADA): A Post-Hoc Analysis of the AWARD-2, -4, and -5 Trials.
    Diabetes Obes Metab. 2018 Jan 27. doi: 10.1111/dom.13237.
    PubMed     Text format     Abstract available


  185. CAO YX, Liu HH, Dong QT, Li S, et al
    Effect of the PCSK9-monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Jan 27. doi: 10.1111/dom.13235.
    PubMed     Text format     Abstract available


  186. RETNAKARAN R, Choi H, Ye C, Kramer CK, et al
    A 2-year Trial of Intermittent Insulin Therapy versus Metformin for the Preservation of Beta-cell Function after Initial Short-term Intensive Insulin Induction in early Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jan 27. doi: 10.1111/dom.13236.
    PubMed     Text format     Abstract available


  187. TANG H, Li G, Zhao Y, Wang F, et al
    Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis.
    Diabetes Obes Metab. 2018 Jan 25. doi: 10.1111/dom.13232.
    PubMed     Text format     Abstract available


  188. LIU H, Wang L, Zhang S, Leng J, et al
    One-year weight losses in the Tianjin Gestational Diabetes Mellitus Prevention Program: A Randomized Clinical Trial.
    Diabetes Obes Metab. 2018 Jan 23. doi: 10.1111/dom.13225.
    PubMed     Text format     Abstract available


  189. KREBS JD, Weatherall M, Corley B, Wiltshire E, et al
    Optimising the management of hypoglycaemia in people with Type 2 Diabetes. A randomised crossover comparison of a weight-based protocol compared with two fixed-dose glucose regimens.
    Diabetes Obes Metab. 2018 Jan 23. doi: 10.1111/dom.13231.
    PubMed     Text format     Abstract available


  190. KOFFERT J, Stahle M, Karlsson H, Iozzo P, et al
    Morbid obesity and type 2 diabetes alter intestinal fatty acid uptake and blood flow.
    Diabetes Obes Metab. 2018 Jan 20. doi: 10.1111/dom.13228.
    PubMed     Text format     Abstract available


  191. APPERLOO EM, Pena MJ, de Zeeuw D, Denig P, et al
    Individual variability in response to renin-angiotensin-aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: a primary care cohort study.
    Diabetes Obes Metab. 2018 Jan 18. doi: 10.1111/dom.13226.
    PubMed     Text format     Abstract available


  192. POLIDORI D, Iijima H, Goda M, Maruyama N, et al
    Intra- and Inter-Subject Variability for Increases in Serum Ketone Bodies in Patients With Type 2 Diabetes Treated With the Sodium Glucose Co-transporter 2 Inhibitor Canagliflozin.
    Diabetes Obes Metab. 2018 Jan 17. doi: 10.1111/dom.13224.
    PubMed     Text format     Abstract available


  193. DORENBOS E, Drummen M, Rijks J, Adam T, et al
    PREVIEW: Prevention of diabetes through lifestyle intervention in a multicentre study in Europe in children (10-17y). Design, methods, and baseline results.
    Diabetes Obes Metab. 2018 Jan 11. doi: 10.1111/dom.13216.
    PubMed     Text format     Abstract available


  194. ILANY J, Bhandari H, Nabriski D, Toledano Y, et al
    Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled on once daily basal insulin: a randomized, phase IV study.
    Diabetes Obes Metab. 2018 Jan 8. doi: 10.1111/dom.13214.
    PubMed     Text format     Abstract available


  195. PORKSEN NK, Linnebjerg H, Lam ECQ, Garhyan P, et al
    Basal Insulin Peglispro Increases Lipid Oxidation, Metabolic Flexibility, Thermogenesis And Ketone Bodies Compared To Insulin Glargine In Subjects With Type 1 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Jan 8. doi: 10.1111/dom.13215.
    PubMed     Text format     Abstract available


  196. MATHIEU C, Bode BW, Franek E, Philis-Tsimikas A, et al
    Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): a 52-week, randomized, treat-to-target, phase 3 trial.
    Diabetes Obes Metab. 2018 Jan 8. doi: 10.1111/dom.13205.
    PubMed     Text format     Abstract available


  197. TERAUCHI Y, Tamura M, Senda M, Gunji R, et al
    Long-term safety and efficacy of tofogliflozin add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicenter, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13213.
    PubMed     Text format     Abstract available


  198. JABBOUR SA, Frias JP, Guja C, Hardy E, et al
    Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13206.
    PubMed     Text format     Abstract available


  199. MENEGHINI LF, Lee L, Gupta S, Preblick R, et al
    The association of hypoglycaemia severity and clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin.
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13208.
    PubMed     Text format     Abstract available


  200. PACKER M
    Have We Really Demonstrated the Cardiovascular Safety of Antihyperglycemic Drugs? Rethinking the Concepts of Macrovascular and Microvascular Disease in Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13207.
    PubMed     Text format     Abstract available


    December 2017
  201. PETTUS J, Reeds D, Santos Cavaiola T, Boeder S, et al
    Effect of a Glucagon Receptor Antibody (REMD-477) in Type 1 Diabetes: A Randomized Controlled Trial.
    Diabetes Obes Metab. 2017 Dec 28. doi: 10.1111/dom.13202.
    PubMed     Text format     Abstract available


  202. ZHOU FL, Xie L, Pan C, Wang Y, et al
    Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiated on basal insulin.
    Diabetes Obes Metab. 2017 Dec 26. doi: 10.1111/dom.13200.
    PubMed     Text format     Abstract available


  203. WINDING KM, Munch GW, Iepsen UW, Van Hall G, et al
    The effect of low-volume high-intensity interval training versus endurance training on glycemic control in individuals with type 2 diabetes.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13198.
    PubMed     Text format     Abstract available


  204. ZHOU FL, Ye F, Berhanu P, Gupta VE, et al
    Real-world evidence on clinical and economic outcomes of switching to insulin glargine 300 Units/mL vs other basal insulins in patients with type 2 diabetes on basal insulin.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13199.
    PubMed     Text format     Abstract available


  205. BUMBU A, Moutairou A, Matar O, Fumeron F, et al
    Non-severe hypoglycemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13197.
    PubMed     Text format     Abstract available


  206. CHON S, Rhee SY, Ahn KJ, Baik SH, et al
    Long-term outcome on glycaemic control and beta-cell preservation of early intensive treatment in patients with newly diagnosed Type 2 Diabetes: A Multicentre Randomised Trial.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13196.
    PubMed     Text format     Abstract available


  207. PRATLEY RE, Eldor R, Raji A, Golm G, et al
    Ertugliflozin Plus Sitagliptin Versus Either Individual Agent Over 52 Weeks in Patients with Type 2 Diabetes Mellitus Inadequately Controlled With Metformin: The VERTIS FACTORIAL Randomized Trial.
    Diabetes Obes Metab. 2017 Dec 21. doi: 10.1111/dom.13194.
    PubMed     Text format     Abstract available


  208. WIGHTMAN SS, Sainsbury CAR, Jones GC
    Visit-to-visit HbA1c variability and systolic blood pressure (SBP) variability are significantly and additively associated with mortality in people with type 1 diabetes: an observational study.
    Diabetes Obes Metab. 2017 Dec 21. doi: 10.1111/dom.13193.
    PubMed     Text format     Abstract available


  209. PACKER M
    Role of the Sodium-Hydrogen Exchanger in Mediating the Renal Effects of Drugs Commonly Used in the Treatment of Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Dec 11. doi: 10.1111/dom.13191.
    PubMed     Text format     Abstract available


  210. ALSALIM W, Goransson O, Carr RD, Bizzotto R, et al
    Effect of a single dose of the DPP-4 inhibitor sitagliptin on beta-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naive, well-controlled type 2 diabetes subjects.
    Diabetes Obes Metab. 2017 Dec 11. doi: 10.1111/dom.13192.
    PubMed     Text format     Abstract available


  211. JI L, Liu J, Yang J, Li Y, et al
    Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naive Chinese patients: analysis of results from the CONSENT trial.
    Diabetes Obes Metab. 2017 Dec 11. doi: 10.1111/dom.13190.
    PubMed     Text format     Abstract available


  212. PRICE H, Bluher M, Prager R, Phan TM, et al
    Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13182.
    PubMed     Text format     Abstract available


  213. ZACCARDI F, Dhalwani NN, Dales J, Mani H, et al
    Comparison of glucose-lowering agents following dual therapy failure in type 2 diabetes Systematic review and network meta-analysis of randomised controlled trials.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13185.
    PubMed     Text format     Abstract available


  214. EL KHOURY P, Roussel R, Fumeron F, Abou-Khalil Y, et al
    Plasma PCSK9 and Cardiovascular Events in Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13181.
    PubMed     Text format    


  215. HOME P, Calvi-Gries F, Blonde L, Pilorget V, et al
    Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13179.
    PubMed     Text format     Abstract available


    November 2017
  216. SISKIND D, Russell AW, Gamble C, Winckel K, et al
    Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: a randomised controlled trial.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13167.
    PubMed     Text format     Abstract available


  217. WANG H, Liu Y, Tian Q, Yang J, et al
    Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: a meta-analysis of randomised controlled trials.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13177.
    PubMed     Text format     Abstract available


  218. LOUGHLIN AM, Qiao Q, Nunes AP, Ohman P, et al
    Effectiveness and tolerability of therapy with exenatide once-weekly versus basal insulin among injectable-naive elderly or renal impaired patients with type 2 diabetes in the United States.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13175.
    PubMed     Text format     Abstract available


  219. HART HUBERTA E, Rutten Guy E, Bontje Kyra N, Vos Rimke C, et al
    Overtreatment of older patients with type 2 diabetes mellitus in primary care.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13174.
    PubMed     Text format     Abstract available


  220. BOTHA S, Forde L, MacNaughton S, Shearer R, et al
    The effect of non-surgical weight management on weight and glycaemic control in people with type 2 diabetes: a comparison of interventional and non-interventional outcomes at three years.
    Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13171.
    PubMed     Text format     Abstract available


  221. TAY J, Thompson CH, Luscombe-Marsh ND, Wycherley TP, et al
    Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high carbohydrate, low fat diet in type 2 diabetes: a 2 year randomized clinical trial.
    Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13164.
    PubMed     Text format     Abstract available


  222. VILSBOLL T, Bain SC, Leiter LA, Lingvay I, et al
    Semaglutide, reduction in HbA1c and the risk of diabetic retinopathy.
    Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13172.
    PubMed     Text format     Abstract available


  223. YE M, Robson PJ, Eurich DT, Vena JE, et al
    Systemic Use of Antibiotics and Risk of Diabetes in Adults: A Nested Case-control Study of Alberta's Tomorrow Project.
    Diabetes Obes Metab. 2017 Nov 20. doi: 10.1111/dom.13163.
    PubMed     Text format     Abstract available


  224. CHEN Y, Liu X, Li Q, Ma J, et al
    Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: results from the SUPER study, a randomized, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2017 Nov 16. doi: 10.1111/dom.13161.
    PubMed     Text format     Abstract available


  225. MCGOVERN A, Tippu Z, Hinton W, Munro N, et al
    A comparison of adherence and persistence by medication class in type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2017 Nov 14. doi: 10.1111/dom.13160.
    PubMed     Text format     Abstract available


  226. TONG L, Pan C, Wang H, Bertolini M, et al
    Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: a longitudinal study of a US administrative claims database.
    Diabetes Obes Metab. 2017 Nov 8. doi: 10.1111/dom.13156.
    PubMed     Text format     Abstract available


  227. CHAN LKY, Wang Y, Ng EKW, Leung PS, et al
    NHE3 Blockade Ameliorates Type 2 Diabetes Mellitus via Inhibition of SGLT1-Mediated Glucose Absorption in the Small Intestine.
    Diabetes Obes Metab. 2017 Nov 7. doi: 10.1111/dom.13151.
    PubMed     Text format     Abstract available


  228. INAGAKI N, Harashima SI, Kaku K, Kondo K, et al
    Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2017 Nov 7. doi: 10.1111/dom.13152.
    PubMed     Text format     Abstract available


  229. JOURDAN T, Park JK, Varga ZV, Paloczi J, et al
    Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy.
    Diabetes Obes Metab. 2017 Nov 6. doi: 10.1111/dom.13150.
    PubMed     Text format     Abstract available


  230. SIEGMUND T, Tentolouris N, Knudsen ST, Lapolla A, et al
    A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes.
    Diabetes Obes Metab. 2017 Nov 6. doi: 10.1111/dom.13149.
    PubMed     Text format     Abstract available


  231. CHEN K, Kang D, Yu M, Zhang R, et al
    Direct head-to-head comparison of glycemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: a meta-analysis of long-term randomized controlled trials.
    Diabetes Obes Metab. 2017 Nov 2. doi: 10.1111/dom.13147.
    PubMed     Text format     Abstract available


  232. HERTROIJS DF, Elissen AM, Brouwers MC, Schaper NC, et al
    A risk score of BMI, HbA1c and triglycerides predicts future glycemic control in type 2 diabetes.
    Diabetes Obes Metab. 2017 Nov 2. doi: 10.1111/dom.13148.
    PubMed     Text format     Abstract available


    October 2017
  233. WITTBRODT E, Kong AM, Moore-Schiltz L, Juneau P, et al
    All-Cause and Diabetes-Related Healthcare Costs among U.S. Adults with Type 2 Diabetes Initiating Exenatide Once Weekly or Insulin Glargine.
    Diabetes Obes Metab. 2017 Oct 30. doi: 10.1111/dom.13145.
    PubMed     Text format     Abstract available


  234. SKOG O, Korsgren O
    On the etiology of type 1 diabetes: Physiological growth in children impacts disease progression.
    Diabetes Obes Metab. 2017 Oct 30. doi: 10.1111/dom.13144.
    PubMed     Text format     Abstract available


  235. KHUNTI K, Kosiborod M
    SGLT 2 inhibitors and cardiovascular outcome studies in Type 2 diabetes: From efficacy to effectiveness.
    Diabetes Obes Metab. 2017 Oct 27. doi: 10.1111/dom.13142.
    PubMed     Text format     Abstract available


  236. CASPARD H, Jabbour S, Hammar N, Fenici P, et al
    Recent Trends in the Prevalence of Type 2 Diabetes and the Association With Abdominal Obesity Lead to Growing Health Disparities in the United States.
    Diabetes Obes Metab. 2017 Oct 27. doi: 10.1111/dom.13143.
    PubMed     Text format     Abstract available


  237. GEYER MC, Rayner CK, Horowitz M, Couper JJ, et al
    Targeting Postprandial Glycaemia in Children with Diabetes: Opportunities and Challenges.
    Diabetes Obes Metab. 2017 Oct 26. doi: 10.1111/dom.13141.
    PubMed     Text format     Abstract available


  238. HUANG J, Yang Y, Hu R, Chen L, et al
    Anti-interleukin-1 therapy has mild hypoglycemic effect in type 2 diabetes.
    Diabetes Obes Metab. 2017 Oct 26. doi: 10.1111/dom.13140.
    PubMed     Text format     Abstract available


  239. SHAH A, Levesque K, Pierini E, Rojas B, et al
    Effect of Sitagliptin on Glucose Control in Type 2 Diabetes Mellitus after Roux-en-Y Gastric Bypass Surgery.
    Diabetes Obes Metab. 2017 Oct 26. doi: 10.1111/dom.13139.
    PubMed     Text format     Abstract available


  240. HWANG YC, Morrow DA, Cannon CP, Liu Y, et al
    High-sensitivity C-reactive Protein, Low-Density Lipoprotein Cholesterol, and Cardiovascular Outcomes in Patients with Type 2 Diabetes in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) Trial.
    Diabetes Obes Metab. 2017 Oct 24. doi: 10.1111/dom.13136.
    PubMed     Text format     Abstract available


  241. TANG T, Abbott S, le Roux CW, Wilson V, et al
    Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis.
    Diabetes Obes Metab. 2017 Oct 20. doi: 10.1111/dom.13131.
    PubMed     Text format     Abstract available


  242. HENRY R, Rosenstock J, McCarthy JF, Carls G, et al
    Treatment Satisfaction with ITCA 650, a Novel Drug-device Delivering Continuous Exenatide versus Twice-Daily Injections of Exenatide in Type 2 Diabetics on Metformin.
    Diabetes Obes Metab. 2017 Oct 20. doi: 10.1111/dom.13133.
    PubMed     Text format     Abstract available


  243. TOP W, Stehouwer C, Lehert P, Kooy A, et al
    Metformin and beta cell function in insulin-treated patients with type 2 diabetes : a randomized placebo-controlled 4.3 year trial.
    Diabetes Obes Metab. 2017 Oct 2. doi: 10.1111/dom.13123.
    PubMed     Text format     Abstract available


    September 2017
  244. JABBOUR S, Seufert J, Scheen A, Bailey CJ, et al
    Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from Phase 2b/3 clinical trials.
    Diabetes Obes Metab. 2017 Sep 26. doi: 10.1111/dom.13124.
    PubMed     Text format     Abstract available


  245. MARFELLA R, Sardu C, Calabro P, Siniscalchi M, et al
    Non-ST-Elevation Myocardial Infarction (NSTEMI) outcome in type 2 diabetic patients with non-obstructive coronary artery stenosis: effects of incretin treatment.
    Diabetes Obes Metab. 2017 Sep 26. doi: 10.1111/dom.13122.
    PubMed     Text format     Abstract available


  246. PANG B, Zhao LH, Li XL, Song J, et al
    Different intervention strategies for preventing type 2 diabetes mellitus in China: A systematic review and network meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2017 Sep 23. doi: 10.1111/dom.13121.
    PubMed     Text format     Abstract available


  247. HULST AH, Polderman JAW, Ouweneel E, Pijl AJ, et al
    Perioperative continuation of metformin does not improve glycemic control in patients with type 2 diabetes; a randomized controlled trial.
    Diabetes Obes Metab. 2017 Sep 20. doi: 10.1111/dom.13118.
    PubMed     Text format     Abstract available


  248. DOU J, Ma J, Liu J, Wang C, et al
    Efficacy and Safety of Saxagliptin in Combination with Metformin as Initial Therapy in Chinese Patients with Type 2 diabetes: Results from the START Study, a Multicenter, Randomized, Double-blind, Active-controlled, Phase 3 Trial.
    Diabetes Obes Metab. 2017 Sep 19. doi: 10.1111/dom.13117.
    PubMed     Text format     Abstract available


  249. DAGOGO-JACK S, Liu J, Eldor R, Amorin G, et al
    Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study.
    Diabetes Obes Metab. 2017 Sep 17. doi: 10.1111/dom.13116.
    PubMed     Text format     Abstract available


  250. LEITER LA, Cariou B, Muller-Wieland D, Colhoun HM, et al
    Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
    Diabetes Obes Metab. 2017 Sep 14. doi: 10.1111/dom.13114.
    PubMed     Text format     Abstract available


  251. YUAN Z, DeFalco FJ, Ryan PB, Schuemie MJ, et al
    Risk of Lower Extremity Amputations in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors in the United States: A Retrospective Cohort Study.
    Diabetes Obes Metab. 2017 Sep 12. doi: 10.1111/dom.13115.
    PubMed     Text format     Abstract available


    March 2017
  252. NEAL B, Perkovic V, Matthews DR, Mahaffey KW, et al
    Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2017;19:387-393.
    PubMed     Text format     Abstract available


  253. DRIESSEN JH, van den Bergh JP, van Onzenoort HA, Henry RM, et al
    Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
    Diabetes Obes Metab. 2017;19:421-428.
    PubMed     Text format     Abstract available


  254. KOZLOVSKI P, Fonseca M, Mohan V, Lukashevich V, et al
    Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies.
    Diabetes Obes Metab. 2017;19:429-435.
    PubMed     Text format     Abstract available


  255. CAMASTRA S, Astiarraga B, Tura A, Frascerra S, et al
    Effect of exenatide on postprandial glucose fluxes, lipolysis, and ss-cell function in non-diabetic, morbidly obese patients.
    Diabetes Obes Metab. 2017;19:412-420.
    PubMed     Text format     Abstract available


  256. KNAPEN LM, de Jong RG, Driessen JH, Keulemans YC, et al
    Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
    Diabetes Obes Metab. 2017;19:401-411.
    PubMed     Text format     Abstract available


  257. BAIN S, Druyts E, Balijepalli C, Baxter CA, et al
    Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.
    Diabetes Obes Metab. 2017;19:329-335.
    PubMed     Text format     Abstract available


  258. BETTGE K, Kahle M, Abd El Aziz MS, Meier JJ, et al
    Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
    Diabetes Obes Metab. 2017;19:336-347.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: